Health Care

Fresenius sells 7.8 m FMC shares for €300 m, cutting debt and boosting core growth—strengthening credit, improving margins, and positioning for value‑based care.

Healthcare gains powered by Moderna, Merck, Lilly and others lift the S&P 500, showing how drug approvals, market‑access deals and M&A fuel sector resilience.

Discover how AstraZeneca’s strategic M&A, pipeline resilience, and market‑access gains keep investors confident amid patent cliffs and fierce competition.

Illumina’s recent Rule 144 filing shows a routine insider RSU sale, offering insights into the company’s equity strategy, market confidence, and biotech insider trends.

Argenx’s Phase 3 win for VYVGART in autoimmune myositis shows promise, but regulatory, payer, and competitive hurdles could limit its commercial impact.

BioArctic AB teams with Mesenkia to bring BBB‑penetrating antibody therapy to glioblastoma, expanding its portfolio and boosting investor confidence.

AbbVie’s new shareholder shift highlights its battle against the Humira patent cliff, market‑access pressures, and M&A prospects—insights on future growth and strategy.

How Bayer’s postponed $7.25 billion Roundup lawsuit clashes with its crop‑science investor event—and what that means for investors and the DAX.

German DAX lingers near 26,091 amid rising bond yields, a stronger euro, and sector swings—pharma resilience, tech gains, and semiconductor pain paint the 2026 outlook.

Pfizer’s Q1 earnings reveal oncology & obesity growth, cost‑saving plans, and a shift from COVID‑19 sales, boosting share price and long‑term prospects.